Involved in the tyrosine degradation pathway, 4-hydroxyphenylpyruvate dioxygenase (HPPD) is an important target for treating type I tyrosinemia. To discover novel HPPD inhibitors, we proposed a hydrophobicity-oriented drug design (HODD) strategy based on the interactions between HPPD and the commercial drug NTBC. Most of the new compounds showed improved activity, compound d23 being the most active candidate (IC = 0.047 μM) with about 2-fold more potent than NTBC (IC = 0.085 μM). Therefore, compound d23 is a potential drug candidate to treat type I tyrosinemia.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ejmech.2019.01.032 | DOI Listing |
Publication Analysis
Top Keywords
hydrophobicity-oriented drug
8
drug design
8
design hodd
8
4-hydroxyphenylpyruvate dioxygenase
8
type tyrosinemia
8
compound d23
8
hodd human
4
human 4-hydroxyphenylpyruvate
4
dioxygenase inhibitors
4
inhibitors involved
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!